Ken Griffin’s Mineralys Therapeutics MLYS Stock Holding History

Ken Griffin’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.3M	Buy	600,041 +200,122	+50%	+$5.87M	﹤0.01%	2593
2025 Q4	$14.5M	Sell	399,919 -1,667,308	-81%	-$66.9M	﹤0.01%	2742
2025 Q3	$78.4M	Buy	2,067,227 +2,052,845	+14,274%	+$44.4M	0.01%	1021
2025 Q2	$195K	Sell	14,382 -129,980	-90%	-$1.88M	﹤0.01%	10702
2025 Q1	$2.29M	Buy	+144,362	New	+$1.66M	﹤0.01%	5280
2024 Q4	–	Sell	-3,136	Closed	-$38K	–	15053
2024 Q3	$38K	Sell	3,136 -9,898	-76%	-$120K	﹤0.01%	12198
2024 Q2	$152K	Buy	13,034 +12,937	+13,337%	+$163K	﹤0.01%	10326
2024 Q1	$1.25K	Sell	97 -115,206	-100%	-$1.42M	﹤0.01%	14155
2023 Q4	$992K	Buy	115,303 +96,687	+519%	+$759K	﹤0.01%	6703
2023 Q3	$177K	Buy	+18,616	New	+$243K	﹤0.01%	10113
2023 Q2	–	Sell	-191,048	Closed	-$2.99M	–	14896
2023 Q1	$2.99M	Buy	+191,048	New	+$3.22M	﹤0.01%	4637

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Ken Griffin's MLYS Position: Q1 2026 in Review

Ken Griffin increased its Mineralys Therapeutics (MLYS) stake by 50% in Q1 2026, buying an estimated $5.87M and bringing the position to 600,041 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2593.

Ken Griffin first reported a position in MLYS in Q1 2023 and has held it in 11 quarters since. The position peaked at $78.4M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Ken Griffin held 600,041 shares of Mineralys Therapeutics worth $16.3M as of Q1 2026.
Ken Griffin bought 200,122 Mineralys Therapeutics shares in Q1 2026, an estimated $5.87M.
Mineralys Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2593 holding.
Ken Griffin first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 11 quarters since.
Ken Griffin's Mineralys Therapeutics position peaked at $78.4M in Q3 2025.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.